Sec Form 4 Filing - Dethlefs Sven @ TEVA PHARMACEUTICAL INDUSTRIES LTD - 2022-03-04

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Dethlefs Sven
2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP, North America Commercial
(Last) (First) (Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,
3. Date of Earliest Transaction (MM/DD/YY)
03/04/2022
(Street)
TEL AVIV, L36944020
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares( 1 ) 03/04/2022 M 37,939 A 137,396 D
Ordinary Shares( 1 ) 03/04/2022 M 13,930 A 151,326 D
Ordinary Shares( 1 ) 03/04/2022 S( 3 ) 3,904( 4 ) D $ 7.4825( 5 ) 147,422 D
Ordinary Shares( 1 ) 03/05/2022 M 24,952 A 172,374 D
Ordinary Shares( 1 ) 03/07/2022 S( 3 ) 6,993( 4 ) D $ 7.3667( 6 ) 165,381 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units ( 2 ) 03/04/2022 M 37,939 ( 7 ) ( 7 ) Ordinary Shares( 1 ) 37,939 $ 0 0 D
Restricted Share Units ( 2 ) 03/04/2022 M 13,930 ( 8 ) ( 8 ) Ordinary Shares( 1 ) 13,930 $ 0 13,931 D
Restricted Share Units ( 2 ) 03/04/2022 A 154,155 ( 9 ) ( 9 ) Ordinary Shares( 1 ) 154,155 $ 0 154,155 D
Restricted Share Units ( 2 ) 03/05/2022 M 24,952 ( 10 ) ( 10 ) Ordinary Shares( 1 ) 24,952 $ 0 74,857 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Dethlefs Sven
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV, L36944020
EVP, North America Commercial
Signatures
/s/ Dov Bergwerk as attorney-in-fact for Sven Dethlefs 03/08/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
( 2 )Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
( 3 )The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
( 4 )Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vestingof the restricted share units listed in Table II.
( 5 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
( 6 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
( 7 )Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
( 8 )Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.
( 9 )Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541vesting on March 4, 2026.
( 10 )Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.